Lilly’s latest China drug deal; Immunovant’s setback in lupus

PartnershipNeutral

AI Analysis

Summary

Eli Lilly entered its fourth China-focused alliance valued up to $3.35 billion since January 2025. Meanwhile, Immunovant faced a setback in lupus development while Vertex's prospects improved and an RNA drug showed success in rare ALS.

Importance:6/10

Sentiment:

0.20

China partnershipdrug developmentallianceclinical setbackrare disease

Related Companies

$LLY $VRTX

Read the original article

Published by BioPharma Dive on September 24, 2026 2:14 PM

Read Original